BioXcel Therapeutics Inc
NASDAQ:BTAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BioXcel Therapeutics Inc
Long-Term Debt
BioXcel Therapeutics Inc
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BioXcel Therapeutics Inc
NASDAQ:BTAI
|
Long-Term Debt
$84.7m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Long-Term Debt
$58.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Long-Term Debt
$22.1B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Long-Term Debt
$50B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Long-Term Debt
$106.7m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-18%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Long-Term Debt
$2.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
22%
|
|
BioXcel Therapeutics Inc
Glance View
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The company is headquartered in New Haven, Connecticut and currently employs 89 full-time employees. The company went IPO on 2018-03-08. The company is focused on utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. Its two advanced clinical development programs are BXCL501, which is an investigational, orally dissolving, sublingual thin film formulation of the adrenergic receptor agonist dexmedetomidine (Dex) for the treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, which is an investigational orally administered systemic innate immune activator for the treatment of castration resistant prostate cancer and advanced solid tumors that are refractory or treatment nave to checkpoint inhibitors. The company is conducting a Phase 1b/2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) for metastatic castration-resistant prostate cancer (mCRPC), in patients with adenocarcinoma and in patients with the aggressive variant small-cell neuroendocrine carcinoma.
See Also
What is BioXcel Therapeutics Inc's Long-Term Debt?
Long-Term Debt
84.7m
USD
Based on the financial report for Dec 31, 2025, BioXcel Therapeutics Inc's Long-Term Debt amounts to 84.7m USD.
What is BioXcel Therapeutics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-3%
Over the last year, the Long-Term Debt growth was -17%. The average annual Long-Term Debt growth rates for BioXcel Therapeutics Inc have been -3% over the past three years .
